Next-Generation Nanobody Platform Targeting CD3 Complex and CEACAM5 for Cancer Immunotherapy

VHH-P713 is a humanized bispecific nanobody designed to target both the CD3 Complex (T Cell Receptor Complex) and CEA cell adhesion molecule 5 (CEACAM5). Currently in the Biological Testing stage, this innovative therapeutic candidate holds strong potential for the treatment of cancer. By simultaneously engaging the CD3 Complex, crucial for T cell activation, and CEACAM5, which is overexpressed in various tumors, VHH-P713 aims to bridge immune effector cells to malignant cells, fueling targeted cytotoxicity. The utilization of a nanobody format enables high tissue penetration and specificity, highlighting its promise as a next-generation immunotherapeutic approach against cancer.

Licensing Opportunity

VHH-P713 is available for licensing and strategic partnerships. We welcome inquiries from organizations interested in collaborating to advance this promising nanobody-based cancer immunotherapy to clinical development and commercialization.

Development Phase

Modality

VHH-P713 is a bispecific, cysteine-engineered antibody built on a nanobody scaffold. Its architecture features a variable heavy chain domain that binds CEACAM5, fused at the C-terminus of an antigen-binding fragment directed against CD3. The molecule is further optimized with 20K polyethylene glycol conjugation, which supports in vivo stability and extends circulatory half-life. The single-domain design grants nanobodies like VHH-P713 a small molecular size, superior tissue permeability, and high solubility, which are highly advantageous for targeting solid and hematological cancers. These properties enable robust tumor infiltration while minimizing off-target effects, supporting its use as a versatile, next-generation cancer therapeutic.

Target

CD3 Complex and CEACAM5 are the dual molecular targets of VHH-P713. CD3 Complex is a critical component of the T cell receptor signaling machinery, predominantly expressed on T lymphocytes and essential for T cell activation. CEACAM5 is a glycoprotein found overexpressed on the surface of multiple epithelial-derived cancers, including colorectal, pancreatic, and lung malignancies. The selective expression pattern of CEACAM5 on tumor cells, combined with the pivotal immune role of CD3 Complex, presents a rational strategy for cancer therapy. VHH-P713 leverages this by simultaneously engaging CD3 Complex to trigger T cell responses and directing those immune effectors towards CEACAM5-expressing cancer cells. This dual targeting heightens tumor-specific cytotoxicity and represents a strategic asset for precision oncology.

Mechanism of Action

VHH-P713 functions as a T-cell engager by binding to CD3 Complex on T cells and CEACAM5 on tumor cells, facilitating immune synapse formation between cytotoxic T lymphocytes and malignant cells. Upon engagement, VHH-P713 modulates intracellular signal transduction via CD3 Complex, resulting in T cell activation and directed cytolytic activity against CEACAM5-expressing cancer cells. This bispecific nanobody approach has the potential to overcome resistance to monotherapies by redirecting the immune response with high specificity. Furthermore, the nanobody platform used in VHH-P713 may be adapted for advanced therapeutic designs, including antibody-drug conjugates or other bispecific formats, providing a robust foundation for future immuno-oncology innovations.

Cancer

Cancer encompasses a collection of diseases characterized by uncontrolled cellular proliferation and the ability to invade or spread to distant sites. It remains a leading cause of morbidity and mortality worldwide, with millions of new diagnoses annually. Current mainstays of cancer therapy include surgery, radiotherapy, chemotherapy, targeted therapies, and immunotherapies. However, existing treatments may be limited by systemic toxicity, resistance, and lack of tumor selectivity. There exists a significant unmet need for approaches that combine specificity, efficacy, and safety. The emergence of immunotherapeutic strategies, such as bispecific T-cell engagers, has demonstrated potential in harnessing the patient’s immune system to selectively eliminate tumor cells. VHH-P713, through its dual targeting of immune and tumor cell markers, embodies this paradigm and could offer a differentiated, more precise treatment option for patients with cancers expressing CEACAM5.